CAM
CYTK icon

CG Asset Management’s Cytokinetics CYTK Stock Holding History

CG Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,248
Closed -$97K – 135
2014
Q1 		$97K Sell
10,248
-1
-0% -$9 0.04% 125
2013
Q4 		$67K Buy
+10,249
New +$67.3K 0.03% 126

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

CG Asset Management's CYTK Position: Q2 2014 in Review

CG Asset Management sold out of Cytokinetics (CYTK) in Q2 2014, closing a stake of 10,248 shares — an estimated $97K sold.

CG Asset Management first reported a position in CYTK in Q4 2013 and held it in 2 quarters. The position peaked at $97K in Q1 2014. 89 funds tracked by Wall St. Rank hold CYTK as of Q2 2014.

  • CG Asset Management reported no remaining Cytokinetics position as of Q2 2014 after selling out during the quarter.
  • CG Asset Management sold 10,248 Cytokinetics shares in Q2 2014, an estimated $97K.
  • CG Asset Management first reported a position in Cytokinetics in Q4 2013 and held it in 2 quarters.
  • CG Asset Management's Cytokinetics position peaked at $97K in Q1 2014.
  • 89 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2014.

Based on CG Asset Management's 13F filing for Q2 2014, filed 7 Aug 2014.